Source:http://linkedlifedata.com/resource/pubmed/id/11054259
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
15
|
pubmed:dateCreated |
2000-11-28
|
pubmed:databankReference | |
pubmed:abstractText |
HIV-1 envelope sequence variants were RT-PCR amplified from serum samples cryopreserved in San Francisco in 1978-1979. The HIV-1 subtype B env V3-V5 sequences from four homosexual men clustered phylogenetically, with a median nucleotide distance of 2.8%, reflecting a recent common origin. These early U.S. HIV-1 env variants mapped close to the phylogenetic root of the subtype B tree while env variants collected in the United States throughout the 1980s and 1990s showed, on average, increasing genetic diversity and divergence from the subtype B consensus sequence. These results indicate that the majority of HIV-1 currently circulating in the United States may be descended from an initial introduction and rapid spread during the mid- to late 1970s of subtype B viruses with limited variability (i.e., a founder effect). As expected from the starburst-shaped phylogeny of HIV-1 subtype B, contemporary U.S. strains were, on average, more closely related at the nucleic acid and amino acid levels to the earlier 1978-1979 env variants than to each other. The growing levels of HIV-1 genetic diversity, one of multiple obstacles in designing a protective vaccine, may therefore be mitigated by using epidemic founding variants as antigenic strains for protection against contemporary strains.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp120,
http://linkedlifedata.com/resource/pubmed/chemical/HIV envelope protein gp120 (305-321),
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0889-2229
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1463-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11054259-AIDS Vaccines,
pubmed-meshheading:11054259-Base Sequence,
pubmed-meshheading:11054259-DNA, Viral,
pubmed-meshheading:11054259-Drug Design,
pubmed-meshheading:11054259-Genetic Variation,
pubmed-meshheading:11054259-HIV Envelope Protein gp120,
pubmed-meshheading:11054259-HIV Infections,
pubmed-meshheading:11054259-HIV-1,
pubmed-meshheading:11054259-Humans,
pubmed-meshheading:11054259-Male,
pubmed-meshheading:11054259-Molecular Sequence Data,
pubmed-meshheading:11054259-Peptide Fragments,
pubmed-meshheading:11054259-Phylogeny,
pubmed-meshheading:11054259-San Francisco
|
pubmed:year |
2000
|
pubmed:articleTitle |
Apparent founder effect during the early years of the San Francisco HIV type 1 epidemic (1978-1979).
|
pubmed:affiliation |
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87501, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|